FOR years, research on prostate cancer has sought an approach to screening that is more individualized than a one-size-fits-all measurement of the level of prostate-specific antigen in a man’s blood. These efforts are now paying off. That’s why it’s time to re-evaluate the nation’s current approach to prostate cancer. Even though we anticipate 221,000 new…
The 2015 update of the guidelines for prostate cancer from the National Comprehensive Cancer Network (NCCN) marks the 20th annual edition of the guidance. The update contains three major changes, which are related to imaging, molecular testing, and the systemic treatment of castration-resistant disease, said James Mohler, MD, who chairs the NCCN panel for prostate…
The U.S. Preventive Services Task Force (USPSTF) recommends against PSA (prostate specific antigen) screening for prostate cancer. The task force currently gives PSA screening a grade D, meaning that there is moderate or high certainty that the PSA test has no benefit or that the harms outweigh the benefits. This recommendation was first issued in…